Key result
Ellagic acid pretreatment reduces ventricular fibrillation to ~25% vs. ~75% in rat ischemia/reperfusion.
Why the study?
Cerebral ischemia/reperfusion increases reactive oxidative stress in cardiomyocytes and can induce cardiac arrhythmias, prompting investigation into whether ellagic acid protects against these arrhythmias.
Does ellagic acid prevent cardiac arrhythmias in a rat model of cerebral ischemia/reperfusion?
Does ellagic acid prevent cardiac arrhythmias in a rat model of cerebral ischemia/reperfusion?
Ellagic acid pretreatment protects against cardiac arrhythmias and adverse ECG changes induced by cerebral ischemia/reperfusion in a rat model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in cerebral I/R rat models; leaves open translation to human arrhythmia prevention.
BACKGROUND: Cerebral ischemia/reperfusion (I/R) could increase the reactive oxidative stress in the cardiomyocytes. Also, some studies report cardiac arrhythmias following oxidative stressor such as I/R. Hence, this study was aimed to investigate the effects of ellagic acid (EA) against arrhythmias in a cerebral I/R model. MATERIALS AND METHODS: Thirty-two male rats were randomly allocated into four groups: Sham (normal saline, 10 days), EA (100 mg/kg EA, 10 days), I/R (20 min ischemia followed by 30 min reperfusion, 10 days), and EA + I/R (100 mg/kg EA before I/R). In all animals, electrocardiogram (ECG) was recorded pre-ischemia and postischemia on the first and 11th days, respectively. RESULTS: The I/R group showed an abnormally prolonged QTc interval after ischemia compared to the preischemia and control groups. EA administration in the EA+I/R group significantly reduced this prolonged QTc interval (P< 0.01). In the I/R group, ischemic/reperfusion resulted in a prolonged QRS complex and an elevated ST, which EA significantly prevented (P<0.01). In addition, EA significantly prevented the dramatically shortened RR interval induced by reperfusion (P<0.01). The incidence of ventricular fibrillation significantly increased in the I/R group; then it dramatically decreased following the administration of EA (P<0.0001). CONCLUSION: EA pretreatment repaired the adverse effects of I/R on the ECG parameters, which can be attributed to its negative chronotropic effects. EA pretreatment can prevent the cerebral I/R-induced heart arrhythmias.
No takes yet. Share an insight, caveat, or question.
Dianat et al. (2019) studied Cardiac arrhythmias following global cerebral ischemia/reperfusion (n=32). Ellagic acid vs. Ischemia/reperfusion without ellagic acid (or sham) was evaluated on Incidence of ventricular fibrillation (p=<0.01). Ellagic acid pretreatment significantly reduced the incidence of ventricular fibrillation (to 25% compared to 75% in the untreated ischemia/reperfusion group) and prevented abnormal ECG alterations in a rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: